Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Income from Continuing Operations: 2013-2024

Historic Income from Continuing Operations for Soleno Therapeutics (SLNO) over the last 9 years, with Dec 2024 value amounting to -$175.8 million.

  • Soleno Therapeutics' Income from Continuing Operations fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.41%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
  • As of FY2024, Soleno Therapeutics' Income from Continuing Operations stood at -$175.8 million, which was down 353.15% from -$38.8 million recorded in FY2023.
  • Over the past 5 years, Soleno Therapeutics' Income from Continuing Operations peaked at -$24.1 million during FY2022, and registered a low of -$175.8 million during FY2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$38.8 million (2023), whereas its average is -$79.6 million.
  • Data for Soleno Therapeutics' Income from Continuing Operations shows a maximum YoY slumped of 353.15% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Soleno Therapeutics' Income from Continuing Operations stood at -$24.1 million in 2022, then tumbled by 61.04% to -$38.8 million in 2023, then slumped by 353.15% to -$175.8 million in 2024.